A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Society of Interventional Radiology Position Statement: Endovascular Management Deemed An Acceptable Treatment Option for Certain Iliofemoral DVT Patients

The Society of Interventional Radiology (SIR) published a position statement deeming endovascular thrombus removal “an acceptable treatment option in selected patients with acute iliofemoral deep vein thrombosis.” The position statement was published online today on the Journal of Vascular and Interventional Radiology (JVIR) website.

SIR convened a multidisciplinary writing group that conducted a comprehensive literature review. The group used evidence from 84 studies—including randomized trials, systematic reviews and meta-analyses, prospective single-arm studies, and retrospective studies—to develop 17 recommendations to guide the use of endovascular venous intervention for the care of patients with acute iliofemoral DVT.

Among the key recommendations were for physicians to quickly identify DVT and provide prompt and adequate anticoagulation, symptom control and functional recovery at the time of diagnosis. For those with anatomically extensive and clinically severe DVT and low bleeding risk, a form of catheter directed thrombolysis (CDT) is reasonable to use in carefully selected patients after evaluating their co-morbidities and personal preferences.

“Endovascular management has been used to treat select patients with acute iliofemoral DVT for more than 25 years, but newer and better-designed studies have shown us that such interventions are most effective and safest when applied to younger patients with severe DVT symptoms,” said Suresh Vedantham, MD, FSIR, the lead author and an interventional radiologist with the Washington University in St. Louis.

“Most DVT patients will benefit from anticoagulation alone, and can be spared anything more invasive, but for those who are suffering from severe symptoms or are at the highest risk of developing lifestyle-limiting post-thrombotic syndrome, catheter-directed therapies are appropriate and effective in reducing symptom severity early and late,” said Vedantham. Vedantham was the primary investigator on the ATTRACT Trial, the findings of which were published in 2017 and informed the new recommendations. Vedantham lauded the efforts of the international thrombosis research community in conducting several pivotal randomized trials to enable well-informed guidelines, and the strong support of the SIR Foundation in the development and conduct of ATTRACT.

Based on the findings of the ATTRACT trial, the position statement authors recommend against the use of CDT for most patients with DVT that is limited to the tibial, popliteal, and femoral veins, for patients with clinical factors that confer a moderate or high risk for bleeding, and for patients with only mild lower extremity symptoms.

“Patient selection is the most important factor for success in the application of interventional treatments,” said, Kush R. Desai, MD, FSIR, chair of SIR’s Venous Disease Clinical Specialty Council, a co-author of the statement, and an interventional radiologist with Northwestern Medicine in Chicago. “Our recommendations follow the evidence so those who may benefit from endovascular treatment options are quickly identified to receive care and ensure positive outcomes.”

“Timing of intervention for acute deep vein thrombosis is important to optimize outcomes,” said Ronald S. Winokur, MD, FSIR, vice chair of SIR’s Venous Disease Clinical Specialty Council, co-author of the statement, and an interventional radiology with Weill Cornell Medicine in New York. “Clear guidance on patient selection including an understanding of extent of disease and accounting for flow dynamics helps patients receive the best treatment at the right time.”

As further research proceeds, SIR believes that adherence to the recommendations in the position statement allow for the use of endovascular therapy in a manner that optimizes benefit and minimizes harm.

“SIR is dedicated to the evidence-based practice of interventional radiology and ensuring our position statements and guidelines reflect the findings of the latest science so patients receive the best possible care,” said SIR President Parag J. Patel, MD, FSIR, an interventional radiologist with the Medical College of Wisconsin. “Thank you to the authors for their time and energy to ensure that DVT patients have access to the care appropriate for their case and medical history.”

Full statement here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy